{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T05:54:05Z","timestamp":1791525245616,"version":"4.3.4"},"reference-count":97,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2015,2,3]],"date-time":"2015-02-03T00:00:00Z","timestamp":1422921600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2015,2,3]],"date-time":"2015-02-03T00:00:00Z","timestamp":1422921600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1007\/s00520-014-2552-1","type":"journal-article","created":{"date-parts":[[2015,2,2]],"date-time":"2015-02-02T05:31:55Z","timestamp":1422855115000},"page":"1431-1445","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Treatment-related symptom management in patients with multiple myeloma: a review"],"prefix":"10.1007","volume":"23","author":[{"given":"Kathleen","family":"Colson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,2,3]]},"reference":[{"key":"2552_CR1","doi-asserted-by":"crossref","unstructured":"Collins CD (2005) Problems monitoring response in multiple myeloma. Cancer Imaging 5 Spec No A:S119-26","DOI":"10.1102\/1470-7330.2005.0033"},{"key":"2552_CR2","doi-asserted-by":"publisher","first-page":"301","DOI":"10.3322\/CA.57.5.301","volume":"57","author":"JA Katzel","year":"2007","unstructured":"Katzel JA, Hari P, Vesole DH (2007) Multiple myeloma: charging toward a bright future. CA Cancer J Clin 57:301\u2013318","journal-title":"CA Cancer J Clin"},{"key":"2552_CR3","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1046\/j.1365-2141.1998.00930.x","volume":"102","author":"J Blade","year":"1998","unstructured":"Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G, Gertz M, Giralt S, Jagannath S, Vesole D (1998) Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 102:1115\u20131123","journal-title":"Br J Haematol"},{"key":"2552_CR4","doi-asserted-by":"publisher","first-page":"278","DOI":"10.3816\/CLM.2009.n.056","volume":"9","author":"RA Kyle","year":"2009","unstructured":"Kyle RA, Rajkumar SV (2009) Treatment of multiple myeloma: a comprehensive review. Clin Lymphoma Myeloma 9:278\u2013288","journal-title":"Clin Lymphoma Myeloma"},{"key":"2552_CR5","unstructured":"Howlader N, Noone AM, Krapcho M, Garshell J, Neyman N, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (2013) SEER cancer statistics review, 1975\u20132010. National Cancer Institute"},{"key":"2552_CR6","doi-asserted-by":"publisher","first-page":"5501","DOI":"10.1182\/blood-2010-07-298760","volume":"116","author":"AJ Waxman","year":"2010","unstructured":"Waxman AJ, Mink PJ, Devesa SS, Anderson WF, Weiss BM, Kristinsson SY, McGlynn KA, Landgren O (2010) Racial disparities in incidence and outcome in multiple myeloma: a population-based study. Blood 116:5501\u20135506","journal-title":"Blood"},{"key":"2552_CR7","doi-asserted-by":"crossref","unstructured":"San-Miguel JF, Paiva B, Gutierrez NC (2013) New tools for diagnosis and monitoring of multiple myeloma. Am Soc Clin Oncol Educ Book 313\u2013318","DOI":"10.14694\/EdBook_AM.2013.33.e313"},{"issue":"Suppl 1","key":"2552_CR8","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1053\/j.seminhematol.2012.05.003","volume":"49","author":"A Jakubowiak","year":"2012","unstructured":"Jakubowiak A (2012) Management strategies for relapsed\/refractory multiple myeloma: current clinical perspectives. Semin Hematol 49(Suppl 1):S16\u2013S32","journal-title":"Semin Hematol"},{"key":"2552_CR9","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","volume":"111","author":"SK Kumar","year":"2008","unstructured":"Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Zeldenrust SR, Dingli D, Russell SJ, Lust JA, Greipp PR, Kyle RA, Gertz MA (2008) Improved survival in multiple myeloma and the impact of novel therapies. Blood 111:2516\u20132520","journal-title":"Blood"},{"key":"2552_CR10","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/j.1365-2141.2011.08574.x","volume":"154","author":"JA Snowden","year":"2011","unstructured":"Snowden JA, Ahmedzai SH, Ashcroft J, D\u2019Sa S, Littlewood T, Low E, Lucraft H, Maclean R, Feyler S, Pratt G, Bird JM, Haemato-oncology Task Force of British Committee for Standards in Haematology and UK Myeloma Forum (2011) Guidelines for supportive care in multiple myeloma 2011. Br J Haematol 154:76\u2013103","journal-title":"Br J Haematol"},{"key":"2552_CR11","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/j.1365-2141.2011.08573.x","volume":"154","author":"JM Bird","year":"2011","unstructured":"Bird JM, Owen RG, D\u2019Sa S, Snowden JA, Pratt G, Ashcroft J, Yong K, Cook G, Feyler S, Davies F, Morgan G, Cavenagh J, Low E, Behrens J, Haemato-oncology Task Force of British Committee for Standards in Haematology (BCSH) and UK Myeloma Forum (2011) Guidelines for the diagnosis and management of multiple myeloma 2011. Br J Haematol 154:32\u201375","journal-title":"Br J Haematol"},{"key":"2552_CR12","unstructured":"National Comprehensive Cancer Network (2014) NCCN clinical practice guidelines in oncology, multiple myeloma V2.2014"},{"key":"2552_CR13","doi-asserted-by":"publisher","first-page":"6063","DOI":"10.1182\/blood-2011-02-297325","volume":"117","author":"M Cavo","year":"2011","unstructured":"Cavo M, Rajkumar SV, Palumbo A, Moreau P, Orlowski R, Blade J, Sezer O, Ludwig H, Dimopoulos MA, Attal M, Sonneveld P, Boccadoro M, Anderson KC, Richardson PG, Bensinger W, Johnsen HE, Kroeger N, Gahrton G, Bergsagel PL, Vesole DH, Einsele H, Jagannath S, Niesvizky R, Durie BG, San Miguel J, Lonial S, International Myeloma Working Group (2011) International myeloma working group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood 117:6063\u20136073","journal-title":"Blood"},{"key":"2552_CR14","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1038\/leu.2009.122","volume":"23","author":"A Palumbo","year":"2009","unstructured":"Palumbo A, Sezer O, Kyle R, Miguel JS, Orlowski RZ, Moreau P, Niesvizky R, Morgan G, Comenzo R, Sonneveld P, Kumar S, Hajek R, Giralt S, Bringhen S, Anderson KC, Richardson PG, Cavo M, Davies F, Blade J, Einsele H, Dimopoulos MA, Spencer A, Dispenzieri A, Reiman T, Shimizu K, Lee JH, Attal M, Boccadoro M, Mateos M, Chen W, Ludwig H, Joshua D, Chim J, Hungria V, Turesson I, Durie BG, Lonial S, IMWG (2009) International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. Leukemia 23:1716\u20131730","journal-title":"Leukemia"},{"key":"2552_CR15","unstructured":"International Myeloma Foundation (2012) Multiple myeloma: the patient journey through survivorship. Oncology Nursing Society\u2019s (ONS) 37th Annual Congress"},{"key":"2552_CR16","unstructured":"American Cancer Society (2013) Multiple myeloma. http:\/\/www.cancer.org\/cancer\/multiplemyeloma\/detailedguide\/index. Accessed 22 May 2014"},{"key":"2552_CR17","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1158\/1535-7163.MCT-11-0433","volume":"10","author":"T Hideshima","year":"2011","unstructured":"Hideshima T, Richardson PG, Anderson KC (2011) Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma. Mol Cancer Ther 10:2034\u20132042","journal-title":"Mol Cancer Ther"},{"key":"2552_CR18","unstructured":"Millenium Pharmaceuticals (2012) VELCADE prescribing information"},{"key":"2552_CR19","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1182\/blood-2008-04-149385","volume":"112","author":"AA Argyriou","year":"2008","unstructured":"Argyriou AA, Iconomou G, Kalofonos HP (2008) Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood 112:1593\u20131599","journal-title":"Blood"},{"key":"2552_CR20","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","volume":"12","author":"P Moreau","year":"2011","unstructured":"Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, Grishunina M, Rekhtman G, Masliak Z, Robak T, Shubina A, Arnulf B, Kropff M, Cavet J, Esseltine DL, Feng H, Girgis S, van de Velde H, Deraedt W, Harousseau JL (2011) Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 12:431\u2013440","journal-title":"Lancet Oncol"},{"key":"2552_CR21","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.3324\/haematol.13285","volume":"93","author":"P Moreau","year":"2008","unstructured":"Moreau P, Coiteux V, Hulin C, Leleu X, van de Velde H, Acharya M, Harousseau JL (2008) Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma. Haematologica 93:1908\u20131911","journal-title":"Haematologica"},{"key":"2552_CR22","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1159\/000322866","volume":"79","author":"I Hrusovsky","year":"2010","unstructured":"Hrusovsky I, Emmerich B, von Rohr A, Voegeli J, Taverna C, Olie RA, Pliskat H, Frohn C, Hess G (2010) Bortezomib retreatment in relapsed multiple myeloma - results from a retrospective multicentre survey in Germany and Switzerland. Oncology 79:247\u2013254","journal-title":"Oncology"},{"key":"2552_CR23","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1111\/bjh.12198","volume":"160","author":"MT Petrucci","year":"2013","unstructured":"Petrucci MT, Giraldo P, Corradini P, Teixeira A, Dimopoulos MA, Blau IW, Drach J, Angermund R, Allietta N, Broer E, Mitchell V, Blade J (2013) A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma. Br J Haematol 160:649\u2013659","journal-title":"Br J Haematol"},{"key":"2552_CR24","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1182\/blood-2012-04-403733","volume":"120","author":"P Moreau","year":"2012","unstructured":"Moreau P, Richardson PG, Cavo M, Orlowski RZ, San Miguel JF, Palumbo A, Harousseau JL (2012) Proteasome inhibitors in multiple myeloma: 10\u00a0years later. Blood 120:947\u2013959","journal-title":"Blood"},{"issue":"Suppl 1","key":"2552_CR25","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.1007\/s12032-010-9542-z","volume":"27","author":"F Gay","year":"2010","unstructured":"Gay F, Palumbo A (2010) Management of disease- and treatment-related complications in patients with multiple myeloma. Med Oncol 27(Suppl 1):S43\u2013S52","journal-title":"Med Oncol"},{"key":"2552_CR26","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/S1470-2045(10)70068-1","volume":"11","author":"M Delforge","year":"2010","unstructured":"Delforge M, Blade J, Dimopoulos MA, Facon T, Kropff M, Ludwig H, Palumbo A, Van Damme P, San-Miguel JF, Sonneveld P (2010) Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues. Lancet Oncol 11:1086\u20131095","journal-title":"Lancet Oncol"},{"key":"2552_CR27","unstructured":"Onyx Pharmaceuticals (2012) KRYPOLIS prescribing information"},{"key":"2552_CR28","doi-asserted-by":"crossref","unstructured":"Dytfeld D, Jasielec J, Griffith KA, Lebovic D, Vesole DH, Jagannath S, Al-Zoubi A, Anderson T, Detweiler-Short K, Stockerl-Goldstein K, Ahmed A, Jobkar T, Durecki DE, McDonnell K, Mietzel M, Couriel D, Kaminski M, Vij R, Jakubowiak AJ (2014) Carfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myeloma. Haematologica 99:e162\u2013164","DOI":"10.3324\/haematol.2014.110395"},{"key":"2552_CR29","first-page":"237","volume":"5","author":"K Fostier","year":"2012","unstructured":"Fostier K, De Becker A, Schots R (2012) Carfilzomib: a novel treatment in relapsed and refractory multiple myeloma. Onco Targets Ther 5:237\u2013244","journal-title":"Onco Targets Ther"},{"key":"2552_CR30","doi-asserted-by":"crossref","unstructured":"Singhal S, Siegel DS, Martin T, Vij R, Wang L, Jakubowiak AJ, Lonial S, Kuketi V, Zonder JA, Wong AF, McCulloch L, Bardos AZ, Niesvizky R, Orlowski RZ, Stewart AK, Kotlovker D, Jagannath S (2011) Integrated safety from phase 2 studies of monotherapy carfilzomib in patients with relapsed and refractory multiple myeloma (MM): an updated analysis. Blood 118:abstr 1876","DOI":"10.1182\/blood.V118.21.1876.1876"},{"key":"2552_CR31","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1182\/blood-2012-05-425934","volume":"120","author":"DS Siegel","year":"2012","unstructured":"Siegel DS, Martin T, Wang M, Vij R, Jakubowiak AJ, Lonial S, Trudel S, Kukreti V, Bahlis N, Alsina M, Chanan-Khan A, Buadi F, Reu FJ, Somlo G, Zonder J, Song K, Stewart AK, Stadtmauer E, Kunkel L, Wear S, Wong AF, Orlowski RZ, Jagannath S (2012) A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood 120:2817\u20132825","journal-title":"Blood"},{"key":"2552_CR32","doi-asserted-by":"publisher","first-page":"27-3619-1-27","DOI":"10.1186\/2162-3619-1-27","volume":"1","author":"T Latif","year":"2012","unstructured":"Latif T, Chauhan N, Khan R, Moran A, Usmani SZ (2012) Thalidomide and its analogues in the treatment of multiple myeloma. Exp Hematol Oncol 1:27-3619-1-27","journal-title":"Exp Hematol Oncol"},{"key":"2552_CR33","unstructured":"Celgene (2013) THALDOMID prescribing information"},{"key":"2552_CR34","doi-asserted-by":"crossref","unstructured":"Palumbo A, Facon T, Sonneveld P, Blade J, Offidani M, Gay F, Moreau P, Waage A, Spencer A, Ludwig H, Boccadoro M, Harousseau JL (2008) Thalidomide for treatment of multiple myeloma: 10\u00a0years later 111:3968\u20133977","DOI":"10.1182\/blood-2007-10-117457"},{"key":"2552_CR35","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1158\/1078-0432.CCR-10-1805","volume":"17","author":"S Lonial","year":"2011","unstructured":"Lonial S, Mitsiades CS, Richardson PG (2011) Treatment options for relapsed and refractory multiple myeloma. Clin Cancer Res 17:1264\u20131277","journal-title":"Clin Cancer Res"},{"key":"2552_CR36","unstructured":"Celgene (2013) REVLIMID prescribing information"},{"key":"2552_CR37","doi-asserted-by":"publisher","first-page":"e64354","DOI":"10.1371\/journal.pone.0064354","volume":"8","author":"B Yang","year":"2013","unstructured":"Yang B, Yu RL, Chi XH, Lu XC (2013) Lenalidomide treatment for multiple myeloma: systematic review and meta-analysis of randomized controlled trials. PLoS One 8:e64354","journal-title":"PLoS One"},{"key":"2552_CR38","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1517\/17425255.2012.712685","volume":"8","author":"S Bringhen","year":"2012","unstructured":"Bringhen S, Gay F, Pautasso C, Cerrato C, Boccadoro M, Palumbo A (2012) Evaluation of the pharmacokinetics, preclinical, and clinical efficacy of lenalidomide for the treatment of multiple myeloma. Expert Opin Drug Metab Toxicol 8:1209\u20131222","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2552_CR39","unstructured":"Faiman B (2013) Nursing considerations for patients with multiple myeloma. Clin Care Opt Oncol"},{"key":"2552_CR40","unstructured":"Celgene (2014) POMALYST precribing information"},{"key":"2552_CR41","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1038\/bcj.2013.38","volume":"3","author":"AA Chanan-Khan","year":"2013","unstructured":"Chanan-Khan AA, Swaika A, Paulus A, Kumar SK, Mikhael JR, Rajkumar SV, Dispenzieri A, Lacy MQ (2013) Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma. Blood Cancer J 3:e143","journal-title":"Blood Cancer J"},{"key":"2552_CR42","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1517\/13543784.2012.691164","volume":"21","author":"EM Ocio","year":"2012","unstructured":"Ocio EM, Mateos MV, San-Miguel JF (2012) Novel agents derived from the currently approved treatments for MM: novel proteasome inhibitors and novel IMIDs. Expert Opin Investig Drugs 21:1075\u20131087","journal-title":"Expert Opin Investig Drugs"},{"key":"2552_CR43","unstructured":"United States National Library of Medicine (2014) LiverTox clinical clinical and research information on drug-induced liver injury: drug record, alkylating agents"},{"key":"2552_CR44","unstructured":"International Myeloma Foundation (2007) Understanding dexamethasone and other steroids"},{"key":"2552_CR45","doi-asserted-by":"crossref","unstructured":"Reeder CB, Reece DE, Kukreti V, Mikhael JR, Chen C, Trudel S, Laumann K, Vohra H, Fonseca R, Bergsagel PL, Leis JF, Tiedemann R, Stewart AK (2014) Long-term survival with cyclophosphamide, bortezomib and dexamethasone induction therapy in patients with newly diagnosed multiple myeloma. Br J Haematol 167:563\u2013565","DOI":"10.1111\/bjh.13004"},{"key":"2552_CR46","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1136\/bjo.82.6.704","volume":"82","author":"RM Stanbury","year":"1998","unstructured":"Stanbury RM, Graham EM (1998) Systemic corticosteroid therapy\u2013side effects and their management. Br J Ophthalmol 82:704\u2013708","journal-title":"Br J Ophthalmol"},{"key":"2552_CR47","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","volume":"11","author":"SV Rajkumar","year":"2010","unstructured":"Rajkumar SV, Jacobus S, Callander NS, Fonseca R, Vesole DH, Williams ME, Abonour R, Siegel DS, Katz M, Greipp PR, Eastern Cooperative Oncology Group (2010) Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 11:29\u201337","journal-title":"Lancet Oncol"},{"key":"2552_CR48","unstructured":"Roxane Laboratories (2012) PredniSONE package insert"},{"key":"2552_CR49","doi-asserted-by":"crossref","unstructured":"Richardson PG, Hungria VTM, Yoon S, Beksac M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Guenther A, Nakorn TN, Siritanaratkul N, Schlossman RL, Hou J, Moreau P, Lonial S, Lee JH, Einsele H, Sopala M, Bengoudifa B, Corrado C, San-Miguel JF (2014) Panorama 1: a randomized, double-blind, phase 3 study of panobinostat or placebo plus bortezomib and dexamethasone in relapsed or relapsed and refractory multiple myeloma. ASCO Ann Meet:Abstr 8510","DOI":"10.1200\/jco.2014.32.15_suppl.8510"},{"key":"2552_CR50","doi-asserted-by":"publisher","first-page":"3958","DOI":"10.1158\/1078-0432.CCR-08-2785","volume":"15","author":"HM Prince","year":"2009","unstructured":"Prince HM, Bishton MJ, Harrison SJ (2009) Clinical studies of histone deacetylase inhibitors. Clin Cancer Res 15:3958\u20133969","journal-title":"Clin Cancer Res"},{"key":"2552_CR51","doi-asserted-by":"crossref","unstructured":"Richardson PG, Schlossman RL, Alsina M, Weber DM, Coutre SE, Gasparetto C, Mukhopadhyay S, Ondovik MS, Khan M, Paley CS, Lonial S (2013) PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. Blood 122:2331\u20132337","DOI":"10.1182\/blood-2013-01-481325"},{"key":"2552_CR52","doi-asserted-by":"crossref","unstructured":"Siegel D, Dimopoulos M, Yoon S, Laubach JP, Kaufman JL, Goldschmidt H, Reece D, Leleu X, Durrant S, Offner F, Cavo M, Nagler A, Jagannath S, Houp J, Sun L, Howe J, Wear S, Anderson KC (2012) Vantage 095: final results from a global, single-arm, phase 2B trial of vorinostat in combination with bortezomib in salvage multiple myeloma patients. Eur Hematol Assoc Meet:Abstr 0294","DOI":"10.1182\/blood.V118.21.480.480"},{"key":"2552_CR53","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/S1470-2045(13)70398-X","volume":"14","author":"M Dimopoulos","year":"2013","unstructured":"Dimopoulos M, Siegel DS, Lonial S, Qi J, Hajek R, Facon T, Rosinol L, Williams C, Blacklock H, Goldschmidt H, Hungria V, Spencer A, Palumbo A, Graef T, Eid JE, Houp J, Sun L, Vuocolo S, Anderson KC (2013) Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study. Lancet Oncol 14:1129\u20131140","journal-title":"Lancet Oncol"},{"key":"2552_CR54","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1182\/blood-2011-05-355115","volume":"118","author":"M Dimopoulos","year":"2011","unstructured":"Dimopoulos M, Jagannath S, Yoon SS, Siegel DS, Lonial S, Hajek R, Facon T, Rosinol L, Blacklock H, Goldschmidt H, Hungaria V, Spencer A, Palumbo A, Reece D, Graef T, Houp J, Sun L, Eid JE, Anderson KC (2011) VANTAGE 088: an international, multicenter, randomized, double-blind study of vorinostat (MK-0683) or placebo in combination with Bortezomib in patients with multiple myeloma. Blood 118:368\u2013369","journal-title":"Blood"},{"key":"2552_CR55","doi-asserted-by":"crossref","unstructured":"Raje N, Hari PN, Vogl DT, Jagannath S, Orlowski RZ, Supko JG, Stephenson P, Jones SS, Wheeler C, Lonial S (2012) Rocilinostat (ACY-1215), a selective HDAC6 inhibitor, alone and in combination with Bortezomib in multiple myeloma: preliminary results from the first-in-humans phase I\/II study. ASH Ann Meet:Abstr 4061","DOI":"10.1182\/blood.V120.21.4061.4061"},{"key":"2552_CR56","doi-asserted-by":"crossref","unstructured":"Raje N, Vogl DT, Hari PN, Jagannath S, Jones SS, Supko JG, Leone G, Wheeler C, Orlowski RZ, Richardson PG, Lonial S (2013) ACY-1215, a selective histone deacetylase (HDAC) 6 inhibitor: interim results of combination therapy with Bortezomib in patients with multiple myeloma (MM). ASH Ann Meet:Abstr 759","DOI":"10.1182\/blood.V122.21.759.759"},{"key":"2552_CR57","doi-asserted-by":"crossref","unstructured":"Yee A, Vorhees P, Bensinger WI, Berdeja J, Supko JG, Richardson PG, Jones SS, Patrick G, Wheeler C, Raje N (2013) ACY-1215, a selective histone deacetylase (HDAC) 6 inhibitor, in combination with lenalidomide and Dexamethasone (dex), is well tolerated without dose limiting toxicity (DLT) in patients (Pts) with multiple myeloma (MM) at doses demonstrating biologic activity: interim results of a phase 1b trial. ASH Ann Meet:Abstr 3190","DOI":"10.1182\/blood.V122.21.3190.3190"},{"key":"2552_CR58","doi-asserted-by":"crossref","first-page":"8542","DOI":"10.1200\/jco.2013.31.15_suppl.8542","volume":"31","author":"S Lonial","year":"2013","unstructured":"Lonial S, Jagannath S, Moreau P, Jakubowiak AJ, Raab MS, Facon T, Vij R, Bleickardt E, Reece DE, Benboubker L, Zonder JA, Deng W, Singhal AK, Richardson PGG (2013) Phase (Ph) I\/II study of elotuzumab (Elo) plus lenalidomide\/dexamethasone (Len\/dex) in relapsed\/refractory multiple myeloma (RR MM): updated Ph II results and Ph I\/II long-term safety. J Clin Oncol 31:8542, abstract","journal-title":"J Clin Oncol"},{"key":"2552_CR59","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1200\/JCO.2011.37.2649","volume":"30","author":"S Lonial","year":"2012","unstructured":"Lonial S, Vij R, Harousseau JL, Facon T, Moreau P, Mazumder A, Kaufman JL, Leleu X, Tsao LC, Westland C, Singhal AK, Jagannath S (2012) Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. J Clin Oncol 30:1953\u20131959","journal-title":"J Clin Oncol"},{"key":"2552_CR60","first-page":"73","volume":"120","author":"T Plesner","year":"2012","unstructured":"Plesner T, Lokhorst H, Gimsing P, Nahi H, Lisby S, Richardson PG (2012) Daratumumab, a CD38 monoclonal antibody in patients with multiple myeloma - data from a dose-escalation phase I\/II study. ASH Ann Meet Abstr 120:73","journal-title":"ASH Ann Meet Abstr"},{"issue":"21","key":"2552_CR61","first-page":"1986","volume":"122","author":"T Plesner","year":"2013","unstructured":"Plesner T, Arkenau T, Lokhorst H, Gimsing P, Krejcik J, Lemech C, Minnema MC, Lassen U, Cakana A, Brun NC, Basse L, Palumbo A, Richardson P (2013) Preliminary safety and efficacy data of daratumumab in combination with lenalidomide and Dexamethasone in relapsed or refractory multiple myeloma. Blood 122(21):1986, abstract","journal-title":"Blood"},{"key":"2552_CR62","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3324\/haematol.2010.030759","volume":"96","author":"MS van der Veer","year":"2011","unstructured":"van der Veer MS, de Weers M, van Kessel B, Bakker JM, Wittebol S, Parren PW, Lokhorst HM, Mutis T (2011) Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab. Haematologica 96:284\u2013290","journal-title":"Haematologica"},{"issue":"21","key":"2552_CR63","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1182\/blood.V122.21.284.284","volume":"122","author":"TG Martin","year":"2013","unstructured":"Martin TG, Strickland SA, Glenn M, Zheng W, Daskalakis N, Mikhael JR (2013) SAR650984, A CD38 monoclonal antibody in patients with selected CD38+ hematological malignancies \u2013 data from a dose-escalation phase I study. Blood 122(21):284","journal-title":"Blood"},{"key":"2552_CR64","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/leu.2011.346","volume":"26","author":"PG Richardson","year":"2012","unstructured":"Richardson PG, Delforge M, Beksac M, Wen P, Jongen JL, Sezer O, Terpos E, Munshi N, Palumbo A, Rajkumar SV, Harousseau JL, Moreau P, Avet-Loiseau H, Lee JH, Cavo M, Merlini G, Voorhees P, Chng WJ, Mazumder A, Usmani S, Einsele H, Comenzo R, Orlowski R, Vesole D, Lahuerta JJ, Niesvizky R, Siegel D, Mateos MV, Dimopoulos M, Lonial S, Jagannath S, Blade J, Miguel JS, Morgan G, Anderson KC, Durie BG, Sonneveld P (2012) Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia 26:595\u2013608","journal-title":"Leukemia"},{"key":"2552_CR65","doi-asserted-by":"publisher","first-page":"3518","DOI":"10.1200\/JCO.2008.18.3087","volume":"27","author":"PG Richardson","year":"2009","unstructured":"Richardson PG, Xie W, Mitsiades C, Chanan-Khan AA, Lonial S, Hassoun H, Avigan DE, Oaklander AL, Kuter DJ, Wen PY, Kesari S, Briemberg HR, Schlossman RL, Munshi NC, Heffner LT, Doss D, Esseltine DL, Weller E, Anderson KC, Amato AA (2009) Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol 27:3518\u20133525","journal-title":"J Clin Oncol"},{"key":"2552_CR66","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/sj.leu.2405062","volume":"22","author":"A Palumbo","year":"2008","unstructured":"Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B, Harousseau J, Zonder JA, Cavo M, Zangari M, Attal M, Belch A, Knop S, Joshua D, Sezer O, Ludwig H, Vesole D, Blade J, Kyle R, Westin J, Weber D, Bringhen S, Niesvizky R, Waage A, von Lilienfeld-Toal M, Lonial S, Morgan GJ, Orlowski RZ, Shimizu K, Anderson KC, Boccadoro M, Durie BG, Sonneveld P, Hussein MA, International Myeloma Working Group (2008) Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 22:414\u2013423","journal-title":"Leukemia"},{"key":"2552_CR67","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1182\/blood-2006-01-0154","volume":"108","author":"JA Zonder","year":"2006","unstructured":"Zonder JA, Barlogie B, Durie BG, McCoy J, Crowley J, Hussein MA (2006) Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis. Blood 108:403, author reply 404","journal-title":"Blood"},{"key":"2552_CR68","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1200\/JCO.2005.03.0221","volume":"24","author":"SV Rajkumar","year":"2006","unstructured":"Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR, Eastern Cooperative Oncology Group (2006) Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 24:431\u2013436","journal-title":"J Clin Oncol"},{"key":"2552_CR69","first-page":"826","volume":"89","author":"M Cavo","year":"2004","unstructured":"Cavo M, Zamagni E, Tosi P, Cellini C, Cangini D, Tacchetti P, Testoni N, Tonelli M, de Vivo A, Palareti G, Tura S, Baccarani M (2004) First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica 89:826\u2013831","journal-title":"Haematologica"},{"key":"2552_CR70","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1188\/08.CJON.S1.21-27","volume":"12","author":"S Rome","year":"2008","unstructured":"Rome S, Doss D, Miller K, Westphal J, Nurse Leadership Board IMF (2008) Thromboembolic events associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board. Clin J Oncol Nurs 12:21\u201328","journal-title":"Clin J Oncol Nurs"},{"key":"2552_CR71","unstructured":"Vij R (2011) Treatment-related adverse events in patients with relapsed\/refractory multiple myeloma. Oncology 25(Suppl 2):45\u201355"},{"key":"2552_CR72","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1053\/j.seminhematol.2009.03.006","volume":"46","author":"M Nucci","year":"2009","unstructured":"Nucci M, Anaissie E (2009) Infections in patients with multiple myeloma. Semin Hematol 46:277\u2013288","journal-title":"Semin Hematol"},{"key":"2552_CR73","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/j.1600-0609.2012.01831.x","volume":"89","author":"F Mols","year":"2012","unstructured":"Mols F, Oerlemans S, Vos AH, Koster A, Verelst S, Sonneveld P, van de Poll-Franse LV (2012) Health-related quality of life and disease-specific complaints among multiple myeloma patients up to 10\u00a0yr after diagnosis: results from a population-based study using the PROFILES registry. Eur J Haematol 89:311\u2013319","journal-title":"Eur J Haematol"},{"key":"2552_CR74","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1097\/NCC.0b013e3181f9904d","volume":"34","author":"EA Coleman","year":"2011","unstructured":"Coleman EA, Goodwin JA, Coon SK, Richards K, Enderlin C, Kennedy R, Stewart CB, McNatt P, Lockhart K, Anaissie EJ, Barlogie B (2011) Fatigue, sleep, pain, mood, and performance status in patients with multiple myeloma. Cancer Nurs 34:219\u2013227","journal-title":"Cancer Nurs"},{"key":"2552_CR75","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1188\/08.ONF.461-469","volume":"35","author":"LR Hanna","year":"2008","unstructured":"Hanna LR, Avila PF, Meteer JD, Nicholas DR, Kaminsky LA (2008) The effects of a comprehensive exercise program on physical function, fatigue, and mood in patients with various types of cancer. Oncol Nurs Forum 35:461\u2013469","journal-title":"Oncol Nurs Forum"},{"key":"2552_CR76","unstructured":"National Comprehensive Cancer Network (2014) Cancer-related fatigue version I. 2014"},{"key":"2552_CR77","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1188\/08.CJON.S1.37-51","volume":"12","author":"LC Smith","year":"2008","unstructured":"Smith LC, Bertolotti P, Curran K, Jenkins B, Nurse Leadership Board IMF (2008) Gastrointestinal side effects associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board. Clin J Oncol Nurs 12:37\u201352","journal-title":"Clin J Oncol Nurs"},{"key":"2552_CR78","unstructured":"Wang M, Cheng J (2013) Overview and management of cardiac and pulmonary adverse events in patients with relapsed and\/or refractory multiple myeloma treated with single-agent carfilzomib. Oncology"},{"key":"2552_CR79","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1111\/bcpt.12081","volume":"113","author":"N Chen","year":"2013","unstructured":"Chen N, Ye Y, Liu L, Reyes J, Assaf MS, Kasserra C, Zhou S, Palmisano M (2013) Lenalidomide at therapeutic and supratherapeutic doses does not prolong QTc intervals in the thorough QTc study conducted in healthy men. Basic Clin Pharmacol Toxicol 113:179\u2013186","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"2552_CR80","unstructured":"Colson K (2010) Nursing considerations in the treatment of multiple myeloma. Clin Care Opt"},{"issue":"Suppl 1","key":"2552_CR81","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.6004\/jnccn.2010.0115","volume":"8","author":"PG Richardson","year":"2010","unstructured":"Richardson PG, Laubach JP, Schlossman RL, Mitsiades C, Anderson K (2010) Complications of multiple myeloma therapy, part 1: risk reduction and management of peripheral neuropathy and asthenia. J Natl Compr Cancer Netw 8(Suppl 1):S4\u2013S12","journal-title":"J Natl Compr Cancer Netw"},{"issue":"Suppl 1","key":"2552_CR82","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.6004\/jnccn.2010.0112","volume":"8","author":"R Niesvizky","year":"2010","unstructured":"Niesvizky R, Badros AZ (2010) Complications of multiple myeloma therapy, part 2: risk reduction and management of venous thromboembolism, osteonecrosis of the jaw, renal complications, and anemia. J Natl Compr Cancer Netw 8(Suppl 1):S13\u2013S20","journal-title":"J Natl Compr Cancer Netw"},{"key":"2552_CR83","unstructured":"Kurtin S (2013) Clinical expert commentaries: subcutaneous administration of Bortezomib. Response Assess"},{"key":"2552_CR84","doi-asserted-by":"crossref","unstructured":"Gado K, Domjan G (2013) Quality of life issues of patients with multiple myeloma. InTech open multiple myeloma - a quick reflection on the fast progress:275\u2013288","DOI":"10.5772\/55625"},{"issue":"Suppl","key":"2552_CR85","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1188\/11.S1.CJON.5-8","volume":"15","author":"E Bilotti","year":"2011","unstructured":"Bilotti E, Faiman BM, Richards TA, Tariman JD, Miceli TS, Rome SI, International Myeloma Foundation Nurse Leadership Board (2011) Survivorship care guidelines for patients living with multiple myeloma: consensus statements of the international myeloma foundation nurse leadership board. Clin J Oncol Nurs 15(Suppl):5\u20138","journal-title":"Clin J Oncol Nurs"},{"key":"2552_CR86","doi-asserted-by":"crossref","unstructured":"Palumbo A, Bringhen S, Ludwig H, Dimopoulos MA, Blade J, Mateos MV, Rosinol L, Boccadoro M, Cavo M, Lokhorst H, Zweegman S, Terpos E, Davies F, Driessen C, Gimsing P, Gramatzki M, Hajek R, Johnsen HE, Leal Da Costa F, Sezer O, Spencer A, Beksac M, Morgan G, Einsele H, San Miguel JF, Sonneveld P (2011) Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood 118:4519\u20134529","DOI":"10.1182\/blood-2011-06-358812"},{"issue":"Suppl 1","key":"2552_CR87","first-page":"S42","volume":"51","author":"A Sharma","year":"2005","unstructured":"Sharma A, Lokeshwar N (2005) Febrile neutropenia in haematological malignancies. J Postgrad Med 51(Suppl 1):S42\u2013S48","journal-title":"J Postgrad Med"},{"key":"2552_CR88","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1182\/blood.V68.2.514.514","volume":"68","author":"E Fritz","year":"1986","unstructured":"Fritz E, Ludwig H, Scheithauer W, Sinzinger H (1986) Shortened platelet half-life in multiple myeloma. Blood 68:514\u2013520","journal-title":"Blood"},{"key":"2552_CR89","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1136\/bmj.2.5914.324","volume":"2","author":"P Barkhan","year":"1974","unstructured":"Barkhan P (1974) Blood and neoplastic diseases. Thrombocytopenia. Br Med J 2:324\u2013325","journal-title":"Br Med J"},{"key":"2552_CR90","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1111\/j.1365-2141.2007.06659.x","volume":"138","author":"O Enrico","year":"2007","unstructured":"Enrico O, Gabriele B, Nadia C, Sara G, Daniele V, Giulia C, Antonio S, Mario P (2007) Unexpected cardiotoxicity in haematological bortezomib treated patients. Br J Haematol 138:396\u2013397","journal-title":"Br J Haematol"},{"key":"2552_CR91","unstructured":"Baxer (2013) Cytoxan package insert"},{"key":"2552_CR92","unstructured":"GlaxoSmithKline (2011) ALKERAN package insert"},{"key":"2552_CR93","unstructured":"Boehringer-Ingelheim (2007) Dexamethasone package insert"},{"key":"2552_CR94","doi-asserted-by":"publisher","first-page":"3696","DOI":"10.1200\/JCO.2012.46.7068","volume":"31","author":"JF San-Miguel","year":"2013","unstructured":"San-Miguel JF, Richardson PG, Gunther A, Sezer O, Siegel D, Blade J, LeBlanc R, Sutherland H, Sopala M, Mishra KK, Mu S, Bourquelot PM, Victoria Mateos M, Anderson KC (2013) Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma. J Clin Oncol 31:3696\u20133703","journal-title":"J Clin Oncol"},{"key":"2552_CR95","doi-asserted-by":"crossref","unstructured":"Merck (2013) ZOLINZA package insert","DOI":"10.22233\/20412495.0413.6"},{"key":"2552_CR96","doi-asserted-by":"publisher","first-page":"e202","DOI":"10.1038\/bcj.2014.23","volume":"4","author":"DS Siegel","year":"2014","unstructured":"Siegel DS, Richardson P, Dimopoulos M, Moreau P, Mitsiades C, Weber D, Houp J, Gause C, Vuocolo S, Eid J, Graef T, Anderson KC (2014) Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma. Blood Cancer J 4:e202","journal-title":"Blood Cancer J"},{"key":"2552_CR97","doi-asserted-by":"crossref","unstructured":"Lokhorst H, Plesner T, Gimsing P, Nahi H, Minnema MC, Lassen U, Krejcik J, Laubach J, Lisby S, Basse L, Richardson P (2013) Phase I\/II dose-escalation study of daratumumab in patients with relapsed or refractory multiple myeloma. J Clin Oncol (suppl;abstr 8512)","DOI":"10.1200\/jco.2013.31.15_suppl.8512"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-014-2552-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-014-2552-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-014-2552-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-014-2552-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,18]],"date-time":"2025-05-18T03:45:32Z","timestamp":1747539932000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-014-2552-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,3]]},"references-count":97,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["2552"],"URL":"https:\/\/doi.org\/10.1007\/s00520-014-2552-1","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,3]]},"assertion":[{"value":"5 September 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}